Janet Hoogstraate on Sweden’s role in global biomanufacturing
Sweden has built a strong foundation in life science, with world-class research environments, advanced infrastructure, and skilled professionals. In a recent interview with SwedenBIO, our CEO, Janet Hoogstraate, shared her thoughts on how these strengths can be better promoted to attract international pharmaceutical projects.
Janet chairs SwedenBIO’s working group for process development and manufacturing whereshe challenges the notion that innovation stands on its own, emphasizing that production is what makes it real.
While Sweden is rightly proud of its research excellence, she emphasized the importance of keeping manufacturing in the country to ensure that research investments translate into therapies, jobs, and long-term value for society.
She called for clearer national goals in Sweden’s life science strategy, especially around advanced therapy production and clinical trials. Supporting companies that manufacture in Sweden, whether directly or through partners, helps strengthen the entire ecosystem.
NorthX Biologics is proud to contribute to this effort and to help bring innovation to life through production.
NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX Biologics has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies.
Amarna Therapeutics, a privately held biotechnology company pioneering transformative gene therapies, today announced the formalization of an agreement with NorthX Biologics, a leading biologics manufacturing partner, to accelerate the development ...
NorthX Biologics, a leading Nordic biopharmaceutical Contract, Development, and Manufacturing Organization (CDMO), is pleased to announce a significant growth investment from Signet Healthcare Partners (Signet), a U.S.-based healthcare private equity ...
Biopharmaceutical contract development and manufacturing organization (CDMO) NorthX Biologics is pleased to announce the appointment of Johanna Magnusson as Chief Operating Officer. With over two decades of leadership experience in ...